Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Rosenbloom

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Critical Care Medicine|February 11, 2003
The last, best hopeCory Franklin, Barry Rosenbloom
Gastroenterology|January 31, 2003
Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's diseaseKonstantinos A Papadakis, Barry Rosenbloom, Stephan R Targan
Molecular Genetics and Metabolism Reports|October 26, 2020
Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher diseaseGrant Bonesteele, J Jay Gargus, Emily Curtin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 23, 2013
A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerabilityGregory M Pastores, Barry Rosenbloom, Neal Weinreb, et al.
Blood Cells, Molecules & Diseases|November 12, 2010
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher RegistryBarry Rosenbloom, Manisha Balwani, Jeff M Bronstein, et al.
Lancet (London, England)|March 31, 2015
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trialTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
American Journal of Hematology|June 2, 2017
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher RegistryPramod K Mistry, Julie L Batista, Hans C Andersson, et al.
Blood|February 8, 2017
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapyTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
Molecular Genetics and Metabolism|May 31, 2020
Gaucher disease and SARS-CoV-2 infection: Emerging management challengesPramod Mistry, Manisha Balwani, Deborah Barbouth, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Critical Care Medicine|February 11, 2003
The last, best hopeCory Franklin, Barry Rosenbloom
Gastroenterology|January 31, 2003
Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's diseaseKonstantinos A Papadakis, Barry Rosenbloom, Stephan R Targan
Molecular Genetics and Metabolism Reports|October 26, 2020
Diffuse large B-cell non-Hodgkin's lymphoma in Gaucher diseaseGrant Bonesteele, J Jay Gargus, Emily Curtin, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 23, 2013
A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerabilityGregory M Pastores, Barry Rosenbloom, Neal Weinreb, et al.
Blood Cells, Molecules & Diseases|November 12, 2010
The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher RegistryBarry Rosenbloom, Manisha Balwani, Jeff M Bronstein, et al.
Lancet (London, England)|March 31, 2015
Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trialTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
British Journal of Haematology|May 30, 2012
Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 yearsCarla E M Hollak, Nadia Belmatoug, J Alexander Cole, et al.
American Journal of Hematology|June 2, 2017
Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher RegistryPramod K Mistry, Julie L Batista, Hans C Andersson, et al.
Blood|February 8, 2017
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapyTimothy M Cox, Guillermo Drelichman, Renata Cravo, et al.
Molecular Genetics and Metabolism|May 31, 2020
Gaucher disease and SARS-CoV-2 infection: Emerging management challengesPramod Mistry, Manisha Balwani, Deborah Barbouth, et al.
Pageof 2